Fibrotic diseases are not well-understood. They represent a number of different diseases that are characterized by the development of severe organ fibrosis without any obvious cause, such as the devastating diseases idiopathic pulmonary fibrosis (IPF) and scleroderma. These diseases have a poor prognosis comparable with endstage cancer and are uncurable. Given the phenotypic differences, it was assumed that the different fibrotic diseases also have different pathomechanisms. Here, we demonstrate that many endstage fibrotic diseases, including IPF; scleroderma; myelofibrosis; kidney-, pancreas-, and heart-fibrosis; and nonalcoholic steatohepatosis converge in the activation of the AP1 transcription factor c-JUN in the pathologic fibroblasts. Expression of the related AP1 transcription factor FRA2 was restricted to pulmonary artery hypertension. Induction of c-Jun in mice was sufficient to induce severe fibrosis in multiple organs and steatohepatosis, which was dependent on sustained c-Jun expression. Single cell mass cytometry revealed that c-Jun activates multiple signaling pathways in mice, including pAkt and CD47, which were also induced in human disease. αCD47 antibody treatment and VEGF or PI3K inhibition reversed various organ c-Jun-mediated fibroses in vivo. These data suggest that c-JUN is a central molecular mediator of most fibrotic conditions. c-JUN | anti-CD47 antibody therapy | signaling pathways | fibrotic disease | scleroderma T he fibrotic response is an important component of normal repair processes that, if uncontrolled, can lead to various lifethreatening conditions, like idiopathic pulmonary fibrosis (IPF), primary myelofibrosis, and scleroderma (1) (2) (3) (4) (5) . It is not known whether similar molecular mechanisms are responsible for the fibrotic response in different diseases, and some studies came to conflicting conclusions (6) . The molecular processes driving fibrogenesis are not well-understood, involving but not limited to transforming growth factor B (TGFB), platelet-derived growth factor (PDGF), connective-tissue growth factor (CTGF), vasoactive peptide, integrin signaling, and increased tissue stiffness (7, 8) . At the cellular level, efforts have been made to characterize fibroblasts by molecular markers (9) , and fibrosis is thought to involve the crosstalk of hematopoietic and mesenchymal stroma cells (4, 6) .
Although the few currently available animal models are useful, all of them have certain limitations: e.g., bleomycin-induced lung or skin fibrosis develops acutely in response to chemical injury and is self-resolving; however, human diseases such as idiopathic pulmonary fibrosis or scleroderma are not (10) . A more recent genetic mouse model showed some fibrosis features but predominantly exhibited vasoocclusive alterations more reminiscent of pulmonary artery hypertension (PAH) (11) .
On the other hand, the genetic basis of fibrotic diseases is just emerging but already promises to gain fundamental insights into pathomechanisms: e.g., FAN1 mutations have been associated with kidney fibrosis, PNLAP3 with liver fibrosis, mutations in JAK2, MPL, or calreticulin with bone marrow fibrosis in myeloproliferative neoplasm (12) , and telomerase reverse transcriptase (TERT) and mucin 5B (MUC5B) with lung fibrosis, as well as alterations in DNA methylation, and some microRNAs (5) have been shown to play a role in lung fibrosis. Some of these molecular findings have guided current standard of care treatments in, e.g., lung fibrosis and primary myelofibrosis.
We previously developed mouse models of primary myelofibrosis associated with myeloproliferative disease (13, 14) and wished to investigate their molecular downstream effectors. Gene expression analysis suggested the dysregulation of cJUN, an AP-1 transcription factor that is a well-established regulator of critical cell biological processes and involved in cancer and other human diseases (15, 16) . We subsequently investigated the expression of AP-1 transcription factors in most human fibrotic diseases and found increased c-JUN expression in SMA + fibroblasts. In addition, c-JUN was responsible for the pathologically increased proliferation of fibroblasts of patients with idiopathic pulmonary fibrosis. Based on our observations in patients with various clinical pictures of fibrosis, we generated a mouse model with inducible cJun. In these mice, we were able to induce fibrosis via the c-JUN pathway, which closely resembled the various organ manifestations in patients. Remarkably, we found that fibroblasts selectively responded to c-Jun despite ubiquitous c-Jun expression. Single cell mass cytometry analysis in mouse fibrosis revealed that transcriptional effects of c-Jun lead to a profound rewiring of active
Significance
Severe human fibrotic diseases are devastating and without effective treatments. We found that c-JUN expression is increased in many human fibrotic diseases and that systemic induction of c-Jun in mice resulted in development of fibrosis of multiple organs. These results suggest that many fibrotic diseases share a common pathomechanism that converges on c-Jun induction. Thus, common treatment strategies could potentially be developed for these seemingly different fibrotic disease entities. Moreover, the in vivo c-Jun induction represents a mouse model for these devastating diseases that could be used for preclinical evaluation of candidate antifibrotic treatments. Indeed, we show that blockade of the antiphagocytotic signal CD47 and the AKT and VEGF receptor pathways reverses tissue fibrosis in mice.
signaling pathways, which we exploited for effective therapeutic intervention in mice.
Results c-JUN Is Expressed in All Major Human Fibrotic Conditions. Previously, we had observed the up-regulation of AP-1 transcription factors in a mouse model of polycythemia vera that also recapitulated features of bone marrow fibrosis (14) . We therefore sought to analyze the expression of c-JUN in human fibrotic conditions. Given the cellular heterogeneity in fibrotic lesions, we performed a thorough immunohistochemical analysis. A total of 454 biopsies from patients with different fibrotic conditions were stained with H&E, with trichrome, and with antibodies against Collagen1, c-JUN, and SMA (Fig. 1) . Then, 148 biopsies were analyzed from patients with scleroderma [skin lesions (n = 104), gastrointestinal (n = 38), and heart (n = 6)], 36 biopsies from patients with idiopathic lung fibrosis, 57 biopsies from patients with primary myelofibrosis, 164 biopsies from patients with liver fibrosis [related to nonalcoholic steatohepatitis (NASH)/hemochromatosis, ethanol (ETOH)/hepatitis C (HCV), alpha-1-anti-trypsin (A1A) deficiency, and chronic rejection], and biopsies from kidneys [systemic lupus erythematosus (SLE)-related and reflux-related) and the bladder, the pancreas, and the heart, but also biopsies involving intraabdominal and pleural adhesions; biopsies were matched with normal tissues if available ( Fig. 1 A and B and Fig. S1 A and C). Quantification of the immunofluorescence analysis demonstrated that a much higher fraction of SMA + fibroblasts expressed nuclear c-JUN in all these fibrotic diseases compared with three control conditions (P < 0.0001) (Fig. 1C and Fig. S1A ). Costaining of c-JUN with SMA (smooth muscle, fibroblasts), CK7 (bronchoepithelium), and CD31 (blood vessel endothelium) demonstrated that c-JUN is predominantly expressed in fibroblasts and a subset of bronchoepithelial cells and macrophages but only rarely detected in other cell types in lung biopsies of lung fibrosis patients ( Fig. 1 A and D) . Because the c-JUN-related factor FRA-2 has been previously described in a murine model of pulmonary vasoocclusion and subsequent fibrosis (11), we tested whether FRA-2 would be coexpressed with c-JUN in lung fibrosis and other fibrotic conditions. Indeed, resembling the described mouse model remarkably closely, nuclear FRA2 was readily detectable in biopsies of pulmonary artery hypertension (PAH), in particular in pathologically thickened PAH vessels (Fig. S2A,  Upper) . However, we failed to detect nuclear FRA-2 staining in the majority of fibroblasts in other fibrotic diseases, including the most common interstitial pneumonia-type of idiopathic pulmonary fibrosis (IPF) (Fig. S2A, Lower) .
This finding prompted us to systematically investigate the expression of additional AP-1 transcription factors. Immunohistochemical stains of lung, liver, kidney, bladder, pancreas, and heart fibrosis and visceral adhesions confirmed strong nuclear c-JUN expression. c-JUN was coexpressed with FOS and FOS-B occasionally in IPF, but not nuclear FRA-2 ( Fig. S1 D and E) . None of the remaining AP-1 transcription factors JUNB, JUND, and FRA-1 were detectable (Fig. S1B ).
Pathogenic but Not Normal Fibroblasts Require c-JUN for Rapid
Proliferation. To further investigate a functional role of c-JUN in pathogenic fibrosis, we knocked down c-JUN in primary lungderived fibroblasts isolated from patients with idiopathic pulmonary fibrosis and normal lung tissue with two different hairpins. First, we confirmed that both hairpins achieved substantial decrease of c-JUN mRNA (Fig. S2C ). Both hairpins substantially reduced the proliferation of IPF fibroblasts compared with the control hairpin at various time points after plating (Fig. 1E, filled  bars) . Surprisingly, we found that normal healthy lung-derived fibroblasts do not require c-JUN; they continue to grow upon c-Jun knockdown (Fig. 1F, open bars) . A complex interplay between the immune system and mesenchymal cells is considered important for the pathogenesis of fibrotic conditions (5, 6) . We therefore analyzed lung samples of patients with idiopathic lung fibrosis for the presence of immune cells and observed large numbers of CD68 + macrophages interspersed with c-JUN-expressing fibroblasts (Fig. S2B , Bottom) (Fig. S2D demonstrates specificity of the human c-JUN antibody). This finding raised the question why fibroblasts are not phagocytized by macrophages. We therefore investigated the expression levels of antiphagocytic don't-eat-me signals and found that CD47 was up-regulated on fibroblasts. In contrast, , and 72 h after plating. Data (mean ± SEM) represent four replicates (Student's t test). *P < 0.05, **P < 0.01, ***P < 0.001.
calreticulin, considered an "eat-me" signal, was expressed in macrophages and a subset of bronchoepithelial cells (Fig. S2B , Top, Middle, and Bottom).
c-Jun Induces Widespread Fibrosis in Many Organs. In addition to bone marrow fibrosis (Figs. S3 and S4), detailed histopathologic analysis of systemically c-Jun-induced mice revealed severe fibrosis of the skin, which is illustrated by the blue trichrome staining that reveals that over 80% of the dermis is replaced with extracellular collagen deposition (Fig. 2D, Upper) . Moreover, several gastroenteric organs displayed similarly severe fibrosis in the distal esophagus, stomach, and small intestine (Fig. 2D , Lower). Other organs were much less affected, such as the lung that showed only a mild interstitial fibrosis. Fibrotic alterations of the skin, gastroesophageal junction, and lung are characteristic diagnostic criteria for the human condition of scleroderma. Given the short time window of analysis due to rapid death with systemic induction, we next asked whether tissue-restricted induction of c-Jun may cause fibrosis also in additional organs.
We subsequently established fibrosis restricted to the lung by c-Jun induction via dox aerosol administration. Indeed, this treatment resulted in striking fibrosis, with over 30% of the lung parenchymal tissue replaced with extracellular collagen as shown by trichrome stain (Fig. 2C) . The collagen was distributed in a patchy interstitial pattern peripleurally and surrounding the major airways. This process was reversible when dox administration was discontinued after 21 d, and animals completely resolved the fibrosis and demonstrated normal histopathology at 300 d at study end point (Fig. S5E ). In addition, we did not notice any fibrotic changes after PBS aerosol administration in c-Jun-inducible mice or with dox aerosol in littermate controls lacking c-Jun (Fig. S5D ). In mice with lung fibrosis, inflammatory cells were admixed and comprised of abundant CD68
+ macrophages with fewer lymphocytes, plasma cells, and neutrophils (Fig. 2C , Inset, Lower Left). Because conventional volumetric assessment of lung function proved challenging in these sick mice, we measured CO gas diffusion, which showed a functional impairment in gas exchange (Fig. S5C) . Thus, the characteristic histopathological abnormalities and clinical presentation of mice after lung-restricted c-Jun induction closely recapitulated the human condition of idiopathic pulmonary fibrosis, in particular the most common usual interstitial pneumonia-type.
Next we crossed the tetO-c-Jun allele to Pax8-rtTA mice to accomplish kidney-specific c-Jun induction. After 8 wk on dox water, animals appeared moribund. Histopathologic analysis demonstrated 30 to 40% interstitial fibrosis of the kidney, with abundant abnormal extracellular collagen matrix deposition labeled in blue with trichrome stain and tubular atrophy consistent with a primary tubulointerstitial nephropathy. In addition, serologic markers for kidney function, such as blood urinary nitrate (BUN) and creatinine, were significantly increased ( Fig. 2E and Fig. S5F ).
cJUN expression caused drastic thickening and fibrosis of the bladder wall (80% fibrosis after 38 d of dox in the drinking water in c-Jun BDF1 mice) (Fig. S4B ) and uterus fibrosis (Fig. S4C ).
Development of Steatohepatosis-Like Alterations After c-Jun Induction.
Steatohepatosis is associated with increased fat accumulation in liver cells and considered a precursor of liver cirrhosis/fibrosis. Indeed, 7 to 10 d after systemic c-Jun induction, we noticed small and large vacuoles in the majority of hepatocytes (Fig. 2F and Fig.  S5G ) (which were positive by oil-red O, a stain that highlights lipids) but no fibrosis. We qualitatively assessed liver fat content after cJUN expression in mice and detected 60% micro-and 40% macrovesicular changes in contrast to less than < 5% in noninduced controls. A recent report showed similar liver changes in mice mediated by distinct AP1 dimers; however, unlike our findings, the steatohepatic abnormalities required liver injury (17) .
In summary, these findings demonstrate that c-Jun expression results in fibrosis in virtually all organs.
c-Jun Induces Feedback Loops to Rewire Signaling Pathways in a Cell
Context-Specific Manner. To further explore the molecular pathways involved in c-Jun-induced fibrosis, we performed genome-wide transcriptional profiling. We profiled whole bone marrow 24 h after dox treatment of c-Jun-inducible and control mice in vivo. Strikingly, already at this early time point, many fibrogenesis-associated genes were induced, such as Cdc42, Cxcl12 (also known as Sdf1), Tgfbr1 and -2, Ccl3, Ccl4, Collagen1a1, Collagen1a2, Collagen5a2, and Adiponectin, some of which are involved in migration (Fig. 3A and Fig. S6A) . Among the top 100 up-regulated genes were other representatives of the AP1 family, most notably c-Fos (Fig. S6A) . To confirm our RNA expression data, we tested 43 cytokines and surface epitopes by direct immunofluorescence or flow cytometry and found Cxcl12 (Sdf1), 129/C57BL/6; Bdf1, F1 129/BDF1. The red curve represents c-Jun B6 mice (n = 10, P < 0.0001), and the blue curve c-Jun Bdf1 mice (n = 7 mice, P < 0.0001 by Kaplan-Meyer survival analysis and two independent experiments). (B) Mice (B6) released many pro-and antiinflammatory cytokines in the blood 48 h after dox-mediated ubiquitous c-Jun induction. We quantified 38 mouse cytokines/ chemokines by multiplex assay and found 13 to be increased significantly (**P < 0.01; ns, not significant) as indicated (n = 3 animals per group, repeated once, P values have been calculated by Student's t test). (C) Dox-mediated c-Jun expression in the lung led to "honeycomb" fibrosis reminiscent of human idiopathic lung fibrosis. Fibrotic plaques with extensive interstitial collagen (blue stained areas on trichrome) and intermixed with interstitial macrophages (CD68 + , Inset) were identified peribronchial and subpleural and represented 34% of the surface area. We quantified the trichrome + areas of 10 high power fields (40x), n = 3 animals per group (***P < 0.001). (D) Dox-mediated ubiquitous c-Jun expression led to thickening and fibrosis of the dermal skin and the gastroesophageal junction, a pattern of fibrosis reminiscent of human scleroderma. We quantified fibrosis in the trichrome + areas of 10 high power fields (40x) of trichrome-stained sections (Insets) and detected 89% in the dermal skin and 67% in the stomach wall, n = 5 animals. (E) Kidney-restricted c-Jun expression using a Pax8-rtTA strain resulted in interstitial fibrosis and tubular atrophy (quantified at 30 to 40%) with elevated kidney enzymes as indicated in the table reminiscent of a primary tubulointerstitial nephropathy in patients.
(Insets) High power views (40x) of the abnormal areas. A PASd stain (Top) labels intact basement membranes of glomeruli and tubuli, the H&E stain demonstrates increased interstitial fibrosis (Middle), and a trichrome stain (blue stain) shows abundant abnormal extracellular collagen matrix deposition (Bottom). n = 4 animals. (F) Systemic c-Jun expression caused fatty liver changes of the micro-and macrovesicular type in mice as shown by the small and large intrahepatic orange deposits on Oil-red O and the intracellular vesicles on H&E stains. We quantified 400 hepatocytes for intracellular lipid droplets in representative areas of Oil-Red O-stained liver sections as indicated. ****P < 0.0001; paired Student's t test. All data (Fig. 2 C-F ) (mean ± SEM) represent two replicates of two independent experiments. Representative histology at 20x magnification, n = 4 animals. (Scale bars: 100 μm.)
Cxcr4, Thrombospondin-1, CD51, Vegfr, and CD47 to be increased in c-Jun-expressing cells (SI Results, SI Materials and Methods, and Dataset S1). Specific interrogation of a fibrosis signature using gene set enrichment analysis (GSEA) revealed a significant enrichment in the c-Jun-induced cells (Fig. 3B) . We next asked whether c-Jun, a target of the MAPK/JNK pathway itself, may in turn control the transcription of genes involved in upstream signaling pathways. To that end, we performed ingenuity pathway analysis and found transcriptional up-regulation of the MAPK pathway 24 h post-c-Jun induction (Fig. S6B) . These transcriptional changes indicated that c-Jun once stimulated by upstream mechanisms may induce feedback loops to rewire the intracellular signaling networks that in turn may lead to fibrogenesis. To trace the origin and consequences of c-Junmediated signaling in primary bone marrow stroma, we performed CyTOF (mass cytometry) analysis. Primary bone marrow stroma cells with or without 48 h of c-Jun induction were fixed and stained with 34 metal-conjugated antibodies against fibrogenesisassociated proteins (such as CD104, CD26, Sca1, Pdgfra, Fgfr, Vegfr, AdipoqR2, CD49b, and CD49e), genes up-regulated from transcriptional analysis (such as CD47, Npm1, Dusp1, and thrombospondin), and major signaling pathways related to c-Jun [such as the ERK1/2 MAPK pathway (pERK1/2 and pS6), the p38 pathway (pMAPKAPKII), pJNK, the AKT-mTOR pathway (pAKT and pS6), and Dusp1] (Dataset S1, SI Results, and SI Materials and Methods). The visualizing data using t-Distributed Stochastic Neighbor Embedding (t-SNE) algorithm (viSNE) maps generated based on all 11 surface markers to the dataset showed two clearly distinct subpopulations. One was characterized by high expression of macrophage lineage markers, including CD172a and F4/80. The other subpopulation, CD172a and F4/80-negative cells, exhibited a much higher induction of phospho-c-Jun and c-Juninduced molecules, such as Dusp1 (Fig. 3C and Fig. S6C ). To better understand the effect of c-Jun induction on signaling networks in both subpopulations, we took advantage of the inherent stochasticity at the phosphor-c-Jun level between individual cells within each subpopulation and asked whether the state of a dependent signaling node could be correlated with the abundance of phospho-c-Jun. A conditional density-based algorithm, DREVI, was recently developed for this purpose to provide a way to visualize relationships between signaling nodes, which is well-suited to characterize the rewired signaling network after c-Jun induction (18, 19) . As we show in Fig. 3D and Fig. S6D , this method computed the conditional density of the dependent signaling nodes on the y axis for the corresponding pospho-c-Jun values on the x axis. Among the measured signaling molecules, the DREVI plot revealed a digital type of response in the relationship between phospho-c-Jun and phospho-Akt only 48 h after c-Jun induction in CD172a and F4/80-negative cells, where a sharp transition between low and high phospho-Akt was observed (Fig. 3D) . In contrast, components of MAPK pathways were the major up-regulated genes in the transcriptomic analysis at 24 h. We did not detect any increase in the phospho-Erk phospho-c-Jun relationship before and after c-Jun induction, and our data suggest that c-Jun increased Dusp1 levels, which negatively regulate the MAPK pathway. Remarkably, the F4-80 + cells showed only little response to c-Jun induction. These results demonstrate that the induction of transcriptional regulator c-Jun can rewire intracellular signaling networks by robustly activating the PI3K-Akt pathway while maintaining homeostasis in the MAPK pathway.
Functional Evaluation of Signaling Pathways Mediating the Fibrotic
Response. We next wished to assess the functional relevance of the signaling pathway rewiring induced by transcriptional activation of cJun. To enable systematic pharmacological interrogation, we sought to develop a c-Jun-dependent in vitro assay. We assessed two cell biological parameters in cultured bone marrow-derived stromal cells from c-Jun-inducible mice. First, we assessed cell growth and observed a shortening of the cell doubling time from about 22 d in control to about 2 d in c-Jun-induced fibroblasts (Fig. 4A) . Second, we measured cell migration of marrow-derived stromal cells in a transwell migration assay as a functional readout of c-Jun induction and observed a 100-fold increase in migration at 2 h and 24 h in dox-mediated c-Jun-expressing cells compared with noninduced cells (Fig. 4B) .
Given its much greater dynamic range, we then tested a series of small molecule inhibitors in the transwell migration assay. Consistent with our mass cytometry findings, the c-Jun-induced migration was reduced to almost baseline levels in the presence of PI3K pathway inhibitors but not blockers of MAPK (such as MEK, p38), Jak, mTOR, Notch, hedgehog, GSK3, and EGFR (Fig. 4C) .
Blockade of the VEGF and PI3K Pathways Reverses Marrow and Skin
Fibrosis in Vivo. Encouraged by these findings, we sought to evaluate the efficacy of blocking the PI3K-AKT pathway in c-Jun-mediated fibrosis in vivo. Wortmannin, a potent PI3K inhibitor, was systemically administered to mice (for 14 d) that were induced to express cJun 2 d before drug. Remarkably, this treatment resulted in complete suppression of bone marrow and skin fibrosis (Fig. 4 G, H, and  I) . In addition to the PI3K-AKT pathway, we also tested the effect of blocking the VEGF pathway on c-Jun-induced phenotypes both in vitro and in vivo because we found that VEGF was highly expressed in the primary bone marrow-derived adherent cells (Fig.  S6C) . As shown in Fig. 4 C, J, and K, the specific VEGFR inhibitor PD173074 was able to abolish c-Jun-mediated migration in vitro and significantly decreased bone marrow fibrosis, but not skin fibrosis, in vivo (SI Results and SI Materials and Methods).
Prophagocytic Anti-CD47 Treatment Reduces Fibrosis in Vivo. We had noticed the prominent appearance of infiltrating macrophages in lung fibrosis, both in patient biopsies and in c-Jun-induced mice (Fig. S2B and Fig. 2C ), which enclosed pathogenic fibroblasts expressing the antiphagocytotic CD47 signal (Fig. S2B) . This pattern was reminiscent of macrophages surrounding CD47 + cancer cells or atherosclerotic plaques and raised the question of whether blocking the CD47 signal may stimulate phagocytosis of pathogenic fibroblasts by these infiltrating macrophages (20) . Anti-CD47 antibodies have been shown to eliminate various human cancer cells and atherosclerosis in different preclinical models (21) , but elimination of nontransformed normal cells has not been observed yet. To evaluate whether macrophages could be stimulated to phagocytose fibroblasts, we first tested the effect of blocking anti-CD47 antibodies in vitro. We cocultured primary mouse macrophages with c-Jun-induced primary fibroblasts and observed that, in the presence of anti-CD47 antibodies, the percentage of phagocytosed fibroblasts was indeed significantly increased (Fig.  4D ). These compelling results prompted us to assess the effects of CD47 antibody treatment in our lung-restricted c-Jun fibrosis model. Indeed, daily i.p. injections for 21 d with an anti-CD47 antibody substantially reduced fibrosis (Fig. 4 E and F) . Most importantly, animals administered anti-CD47 antibody treatment survived longer than control group, and their lung function was significantly improved as indicated by normalized carbon monoxide diffusion (Fig. S5C) . These data suggest that macrophages can eliminate even nontransformed cells that contribute to disease formation when antiphagocytotic stimuli are blocked.
Discussion
Here, we report that c-JUN, a well-characterized AP1 transcription factor, is expressed in many different fibrotic diseases. We found decreased proliferation of patient fibroblasts from fibrotic lungs after knockdown of c-JUN. We detected activated c-Jun and Akt as well as up-regulation of CD47 expression in vivo in endstage fibrosis lungs. We further showed that c-Jun can induce rapid and widespread fibrosis in all organs in mice and is also expressed in fibrotic areas of abdominal adhesions in WT mice. c-JUN is widely expressed in skin epithelium and many other epithelial cells, but not highly in stromal cells. c-JUN is also part of the acute phase response cascade, has a role in bone formation, and has a reputation as an oncogene, and its up-regulation has been shown in various cancers (16) . Although c-JUN's role in cell cycle promotion has been well established primarily in vitro (16, 22) , we observed a striking cell context-dependent fibrotic response in vivo. Despite ubiquitous c-Jun induction, we observed primarily fibrotic changes, indicating that the proproliferative and promigratory effects of c-Jun require the specific cellular context of tissue fibroblasts. Systemic induction of c-Jun in hematopoietic precursors caused rapid apoptosis; induction in the liver caused a pronounced hepatosteatosis. This unique c-Jun responsiveness seems to be shared among fibroblasts of many different tissues although fibroblasts are considered highly heterogeneous and tissue-specific (23) . The fibrogenic response in multiple tissues and organs also contrasts with previously developed fibrosis models, suggesting that induction of c-Jun could be a common molecular mechanism across different human fibrotic conditions.
We further provide evidence that the transcription factor c-Jun, which is a downstream target of MAPK-signaling cascades, can itself rewire and stabilize a specific pattern of multiple signaling pathways. We assume that the remodeling of signaling pathways will be different in different cell types, leading to the opposing cell biological effects of c-Jun in different cell types.
Importantly, our mouse model also confirmed the functional relevance of several signaling pathways, some of which were Anti-CD47 increased the phagocytosis rate. Data (mean ± SEM) represent two replicates and two independent experiments; **P < 0.01; paired Student's t test. (E) H&E stain of lung sections of anti-CD47-treated (Left) and untreated (Right) mice after airway-restricted doxycycline delivery, which resulted in c-Jun-induced honeycomb-type lung fibrosis. The fibrosis was histomorphologically reversed with anti-CD47 antibody (MIAP 410, also known as clone 3). (F) Quantification of the extent of fibrosis in lung sections revealed that the residual fibrosis in the treatment group was 5%. n = 3 mice per experiment, two independent experiments; **P < 0.01, paired Student's t test. (G and J) H&E histological analysis revealed that c-Jun-mediated bone marrow fibrosis was eliminated and replaced with normal hematopoietic cells after systemic treatment of PI3K and VEGF pathway antagonists. (H) Quantification of marrow fibrosis of PI3K inhibitor-treated and control mice revealed almost complete absence of fibrosis in treated animals. N = 3 animals, two independent experiments; ***P < 0.001. BM, bone marrow. (K) Quantification of marrow fibrosis of VEGF inhibitor-treated and control mice. n = 3 animals, two independent experiments; **P < 0.01. (I) c-Jun-mediated sclerodermatype dermal skin thickening was substantially reduced with PI3K inhibitor treatment. Data (mean ± SEM) represent n = 3 replicates, two independent experiments; *P < 0.05; paired Student's t test. (Scale bars: 100 μm.) previously associated with fibrosis and were targeted in past clinical trials (23) , and idiopathic pulmonary fibrosis is currently treated with a combination of small molecule inhibitors targeting four different pathways: VEGF/FGFR/PDGFR and TGFBR (1) . This finding suggests that c-Jun may be a central node controlling these essential pathways. Although combination therapy is in principle an attractive strategy, in practice, it is difficult to identify the right combination of pathways to target. In particular, for clinical trials, it is not feasible to evaluate combination therapy in a systematic manner. Our discovery that c-Jun coordinates several signaling pathways leading to fibrosis in vivo provides a unique opportunity to identify all relevant signaling pathways and predict the most effective therapeutic drug combinations. Moreover, it may be possible to develop therapeutic strategies interfering with the activity of c-Jun directly, which would eliminate the need to search for the most effective combination by eliminating the key disease-driving element.
Several other mouse models have been established previously and have served to gain important insight into some specific aspects of disease (4) . The most widely used model is a bleomycininduced lung fibrosis isolated or in combination with the genetic model of Marfan syndrome. This model suggested the involvement of the TGFBR pathway in fibrosis, which we could confirm to also play a role in our c-Jun-induced model. In particular, the genetic model of Marfan syndrome was very instructive regarding the dissection of the contribution of dendritic helper cells toward the pathomechanism of skin and pulmonary fibrosis (4) . Another model system uses carbon tetrachloride (CCl4) or bile duct ligation to study fibrosis in the liver, which has been shown to be linked to loss or constitutive activation of PDGFR-β in stellate cells.
Unlike these mouse models, the c-Jun-induced model is a purely genetically driven model. Importantly, it recapitulates many aspects of the respective human disease conditions and is not limited to one organ system (such as only lung or skin) akin to the multiorgan disease of scleroderma. Furthermore, c-Jun is highly expressed in all human fibrotic conditions analyzed, and thus in vivo c-Jun induction is likely more physiologically relevant than chemical or infectious conditions that are not involved in the pathogenesis of human disease. We would argue for these reasons that our mouse model will be an important tool to further dissect the pathomechanisms leading to human disease.
One such application was our surprising discovery that endogenous macrophages can be exploited to eliminate pathologic fibroblasts. We showed that fibrogenic cells expressed high levels of the self-protective don't-eat-me epitope CD47. It had been shown in various solid cancers and hematopoietic malignancies, and most recently in atherosclerosis, that blockade of CD47 by antibodies or artificial, high-affinity Sirpα analogs prevents this repressive signal in macrophages, leading to their activation and active phagocytosis (24) . The remarkable low toxicity of anti-CD47 treatments, however, suggested that additional alterations in cancer cells are required to induce phagocytosis (21, 25) . Here, we show that this property is not limited to cancer cells because fibrosis was effectively reversed with anti-CD47 treatment by elimination of fibroblasts by macrophages. Studies are needed to identify the common mechanisms between fibrotic cells and cancer cells that allow effectiveness of the anti-CD47 treatment and to identify which other noncancerous diseases may benefit from such a therapy.
In conclusion, our study revealed the unexpected role of c-Jun as a key and selective driver of organ fibrosis in most human fibrotic diseases. Our findings suggest that diverse fibrotic syndromes may have different etiologies but share common pathomechanisms centered around activation of c-Jun. The c-Jun mouse model may well be suitable to further dissect the pathogenesis of all types of pathologic fibrotic conditions and to develop new and effective therapies.
Materials and Methods
Animal studies were approved by Stanford University Administrative Panels for Lab Animal Care (SU-APLAC 30911, 30912, 31026) and human research under IRB11177. We generated the flp-in tetO-c-JUN or flp-in tetO-JUNB transgenic mice as previously described (25) and induced the mice with tetracycline. CyTOF studies were performed in vivo exactly as described (18, 19) . Details can be found in SI Materials and Methods.
